礼来以最高15亿美元收购Calytrix Bio,继续年度并购连招
Lilly adds to buyout streak with $1.5B purchase of startup Calytrix
礼来得克萨斯州总部宣布以最高15亿美元收购位于马萨诸塞州的Calytrix Bio,后者专注于用双价靶向抗体治疗CALR突变驱动的骨髓增殖性肿瘤(MPN)。该交易是礼来这里年的第15笔收购,已累计投入超300亿美元。Calytrix由摩根资产管理生命科学生意部门于去年成立。
An article from
Lilly’s 15th announced company acquisition this year centers around a precision therapy for rare blood disorders known as myeloproliferative neoplasms.
Published Nov. 16, 2026
Eli Lilly is adding to an already prolific streak of biotechnology company acquisitions this year, purchasing on Monday a stealthy startup working on medicines for rare blood cancers.
Lilly is paying up to $1.5 billion to buy Calytrix Bio, a Wellesley, Massachusetts-based biotech working on treatments for slow-growing malignancies known as myeloproliferative neoplasms. Calytrix didn’t disclose how much guaranteed cash is involved in the deal, only noting that the offer includes an upfront payment and subsequent payouts tied to certain unspecified clinical and regulatory milestones.
Calytrix is developing treatments for myelofibrosis and essential thrombocythemia. Both conditions are forms of myeloproliferative neoplasms, which occur when the body overproduces red blood cells, leading to bone marrow scarring, clots and other health problems. These diseases can be treated with blood transfusions or “JAK” inhibitor drugs like Incyte’s Jakafi. Calytrix claims these therapies only manage symptoms and complications, though, leaving an opportunity for drugs that can precisely target disease-causing mutations.
Calytrix has invented a special type of double-barreled antibody it believes to be capable of changing disease trajectory for people whose disease is driven by mutations to a gene called “CALR.” When this mutation occurs, a particular cell-surface protein emerges that can be precisely targeted while sparing healthy tissue. Calytrix is doing so with a “biparatopic” antibody, a drug that binds to two separate sites on the same protein. It didn’t provide additional details on the therapy or its targets.
“Calytrix was founded on the belief that patients with MPNs deserve therapies that do more than manage symptoms," said Brad Prosek, Calytrix’s president and CEO, in a statement. “We look forward to Lilly advancing the program through the clinic and exploring its potential to benefit patients across the disease spectrum.”
The purchase adds to a considerable streak for Lilly, which in an active year for biotech acquisitions has been the biotech sector’s most prolific dealmaker. Including Monday’s purchase, Lilly has spent more than $30 billion this year on 15 company acquisitions, the majority of which were privately held startups. The next-highest totals belong to GSK, Gilead Sciences and Novartis, all of which have bought three drug companies in 2026.
Calytrix was formed last year by a life sciences venture capital arm of J.P. Morgan Asset Management. Westlake BioPartners and Avoro Ventures backed the startup as well.
来源:BioPharma Dive · biopharmadive.com